Home › KEYTRUDA (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award
 

Keywords :   


KEYTRUDA (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award

2015-10-28 13:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy for the treatment of advanced melanoma and metastatic non-small cell lung cancer in patients whose disease has progressed after other therapies, received the Prix Galien USA 2015 Award for Best Biotechnology Product. Language: English Contact: Media:Pamela Eisele, 267-305-3558 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: product usa prix award

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
18.05Unpaid carers being forced to repay 250m to DWP
18.05Weekly Recap: Hempel, Axalta, KANSAI HELIOS Top This Weeks Stories
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
17.05House Republicans release farm bill draft
17.05House Republicans release farm bill draft
More »